Tcr2 Therapeutics Inc
TCR2 THERAPEUTICS INC. Stock, NASDAQ:TCRR
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline comprise TC-220, a TRuC-T cell that targets MUC16 positive solid tumors; TC-310, a dual TRuC-T cells targeting both CD19 and CD22; and TC-410, a dual TRuC-T cell targeting both mesothelin and MUC16. The company has a cooperative research and development agreement with the National Cancer Institute to collaborate on the use of TCR2 proprietary T cell receptor Fusion Construct T cells as a cancer therapeutic agent against mesothelin in Phase I/II clinical trial of TC-210. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.